The goal of this non-interventional study is to investigate the safety, efficacy and tolerability of Ectoin Lozenges Honey Lemon (EHT02) compared to lozenges containing hyaluronic acid and islandic moss in the treatment of acute viral pharyngitis.
The current non-interventional study aims to investigate the efficacy and tolerability of Ectoin Lozenges Honey Lemon in patients suffering from acute viral pharyngitis. Participants receive treatments as part of routine medical care, and participants can choose one of two treatment options: a) Ectoin Lozenges Honey Lemon or b) lozenges containing hyaluronic acid and icelandic moss. Efficacy will be studied by documentation of the following symptoms: * pain on swallowing * hoarseness * urge to cough * dry mouth and throat * redness of oropharynx and larynx * sore throat * impairment of free breathing * general feeling of illness In parallel, participating patients will document their symptoms over the entire study duration in patient diaries. The observation takes place over a period of seven days.
Study Type
OBSERVATIONAL
Enrollment
102
application of Ectoin Lozenges (EHT02) in accordance with the instructions for use
application of the lozenges in accordance with the instructions for use
bitop AG
Dortmund, Germany
Change in Pharyngitis symptom score evaluated by the physician
The intensity of the symptoms will be graded on a continuous numeric scale, i.e. absent-0, severe-10. The following signs and symptoms will be documented: * pain on swallowing * hoarseness * urge to cough * dry mouth and throat * reddening of oropharynx * reddening of larynx * sore throat * impairment of free breathing * patient's general condition
Time frame: day 1 and day 7
Change in Pharyngitis Symptoms evaluated in patient's diaries
The intensity of the symptoms and signs will be graded on a continuous numeric scale, i.e. absent-0, severe-10. The following signs and symptoms will be documented: * pain on swallowing * hoarseness * urge to cough * dry mouth and throat * sore throat * impairment of free breathing * patient's general condition
Time frame: 7 days
Change of Saliva production evaluated by the physician
Assessment on a continuous numeric scale (0-no, 10-yes)
Time frame: day 7
Evaluation how efficient the treatment is judged by physician
Assessment on a continuous numeric scale (0-bad, 10-very good)
Time frame: day 7
Evaluation how efficient the treatment is judged by patient
Assessment on a continuous numeric scale (0-bad, 10-very good)
Time frame: 7 days
Evaluation how treatment is tolerated (judged by physician)
Assessment on a continuous numeric scale (0-bad, 10-very good)
Time frame: day 7
Evaluation how treatment is tolerated (judged by patients)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Assessment on a continuous numeric scale (0-bad, 10-very good)
Time frame: 7 days
Evaluation of compliance evaluated by physician
Assessment on a continuous numeric scale (0-bad, 10-very good)
Time frame: day 7
Incidence of adverse events/serious adverse events
All occuring adverse events/serious adverse events will be documented during the entire study period.
Time frame: 7 days